Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2024 May 29:rs.3.rs-4378197.
doi: 10.21203/rs.3.rs-4378197/v1.

p.L1795F LRRK2 variant is a common cause of Parkinson's disease in Central Europe

Affiliations

p.L1795F LRRK2 variant is a common cause of Parkinson's disease in Central Europe

Miriam Ostrozovicova et al. Res Sq. .

Update in

  • Prevalence and Clinical Characteristics of the LRRK2 p.L1795F Variant in Central Europeans with Early-Onset and Familial Parkinson's Disease.
    Ostrozovicova M, Tamas G, Atputhavadivel A, Dusek P, Grofik M, Han V, Holly P, Jech R, Kalinova K, Klivenyi P, Kovacs N, Kulcsarova K, Kurca E, Lackova A, Lee H, Lewis P, Magocova V, Marekova M, Murphy D, Nagano A, Necpal J, Pinter D, Rabajdova M, Ruzicka E, Serranova T, Smilowska K, Soos K, Straka I, Svorenova T, Valkovic P, Zarubova K, Gdovinova Z, Houlden H, Rizig M, Skorvanek M; CEGEMOD consortium. Ostrozovicova M, et al. Mov Disord Clin Pract. 2025 Aug;12(8):1132-1139. doi: 10.1002/mdc3.70045. Epub 2025 Mar 22. Mov Disord Clin Pract. 2025. PMID: 40119633 Free PMC article.

Abstract

Pathogenic variants in LRRK2 are one of the most common genetic risk factors for Parkinson's disease (PD). Recently, the lesser-known p.L1795F variant was proposed as a strong genetic risk factor for PD, however, further families are currently lacking in literature. A multicentre young onset and familial PD cohort (n = 220) from 9 movement disorder centres across Central Europe within the CEGEMOD consortium was screened for rare LRRK2 variants using whole exome sequencing data. We identified 4 PD cases with heterozygous p.L1795F variant. All 4 cases were characterised by akinetic-rigid PD phenotype with early onset of severe motor fluctuations, 2 receiving LCIG therapy and 2 implanted with STN DBS; all 4 cases showed unsatisfactory effect of advanced therapies on motor fluctuations. Our data also suggest that p.L1795F may represent the most common currently known pathogenic LRRK2 variant in Central Europe compared to the more studied p.G2019S, being present in 1.81% of PD cases within the Central European cohort and 3.23% of familial PD cases. Together with the ongoing clinical trials for LRRK2 inhibitors, this finding emphasises the urgent need for more ethnic diversity in PD genetic research.

Keywords: Genetics; L1795F; LRRK2; Mutation; Parkinson’s disease; Risk factor.

PubMed Disclaimer

Conflict of interest statement

Confiict of Interest The authors declare no confiicts of interest.

Figures

Figure 1
Figure 1
Schematic representation of the LRRK2 gene with highlighted PD-associated pathogenic mutations including the proposed p.L1795F variant.
Figure 2
Figure 2
Pedigrees of LRRK2 p.L1795F positive PD patients. AAO: age at onset; y = years; CP = cerebral palsy;
Figure 3
Figure 3

References

    1. Zimprich A. et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601–607 (2004). - PubMed
    1. Paisán-Ruíz C. et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44, 595–600 (2004). - PubMed
    1. Kluss J. H., Lewis P. A. & Greggio E. Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson’s disease. Expert Opin. Ther. Targets 26, 537–546 (2022). - PubMed
    1. Alessi D. R. & Pfeffer S. R. Leucine-Rich Repeat Kinases. Annu. Rev. Biochem. (2024) doi: 10.1146/annurev-biochem-030122-051144. - DOI - PubMed
    1. Berwick D. C., Heaton G. R., Azeggagh S. & Harvey K. LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same. Mol. Neurodegener. 14, 49 (2019). - PMC - PubMed

Publication types

LinkOut - more resources